Improving Drug Delivery to Primary and Metastatic Brain Tumors: Strategies to Overcome the Blood–Brain Barrier

K. E. Parrish, J. N. Sarkaria, William F Elmquist

Research output: Contribution to journalArticlepeer-review

101 Scopus citations


Brain tumor diagnosis has an extremely poor prognosis, due in part to the blood–brain barrier (BBB) that prevents both early diagnosis and effective drug delivery. The infiltrative nature of primary brain tumors and the presence of micrometastases lead to tumor cells that reside behind an intact BBB. Recent genomic technologies have identified many genetic mutations present in glioma and other central nervous system (CNS) tumors, and this information has been instrumental in guiding the development of molecularly targeted therapies. However, the majority of these agents are unable to penetrate an intact BBB, leading to one mechanism by which the invasive brain tumor cells effectively escape treatment. The diagnosis and treatment of a brain tumor remains a serious challenge and new therapeutic agents that either penetrate the BBB or disrupt mechanisms that limit brain penetration, such as endothelial efflux transporters or tight junctions, are required in order to improve patient outcomes in this devastating disease.

Original languageEnglish (US)
Pages (from-to)336-346
Number of pages11
JournalClinical pharmacology and therapeutics
Issue number4
StatePublished - Apr 2015

Bibliographical note

Funding Information:
J.N.S. has received research funding from Eli Lilly, Genentech, Sanofi Aventis, Beigene, and Basilea. W.F.E. and K.E.P declare no conflict of interest.

Publisher Copyright:
© 2015 American Society for Clinical Pharmacology and Therapeutics.


Dive into the research topics of 'Improving Drug Delivery to Primary and Metastatic Brain Tumors: Strategies to Overcome the Blood–Brain Barrier'. Together they form a unique fingerprint.

Cite this